-
Engineering of an EPHA2-Targeted Monobody for the Detection of Colorectal Cancer. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2024-4-27 Akhil Venu, Ying Zhang, Jihyoun Seong, Yeongjin Hong, Wan-Sik Lee, Jung-Joon Min
Colorectal cancer (CRC) is the third most common cancer worldwide, and is second only to lung cancer with respect to cancer-related deaths. Noninvasive molecular imaging using established markers is a new emerging method to diagnose CRC. The human ephrin receptor family type-A 2 (hEPHA2) oncoprotein is overexpressed at the early, but not late, stages of CRC. Previously, we reported development of an
-
Impact of Prospero Homeobox-1 (PROX-1) οn the Oncogenic Phenotypes of Hepatocellular Carcinoma Cells. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2024-4-27 Ji-Yun Hong, Sun-Young Park, Young-Lan Park, Ga-Ram You, Jae Hyun Yoon, Young-Eun Joo, Sung Kyu Choi, Sung-Bum Cho
Transcriptional factor prospero homeobox-1 (PROX-1) is crucial for the embryonic development of various organs and cell fate specification. It exhibits either an oncogenic or tumor suppressive activity depending on cancer types. However, the relationship between PROX-1 and hepatocellular carcinoma (HCC) remains obscure. This study was conducted to investigate the effect of PROX-1 on the invasive and
-
Germline MYOF1::WNK4 and VPS25::MYOF1 Chimeras Generated by the Constitutional Translocation t(17;19)(q21;p13) in Two Siblings With Myelodysplastic Syndrome. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2024-4-27 Ioannis Panagopoulos, Kristin Andersen, Vidar Stavseth, Synne Torkildsen, Sverre Heim, Maren Randi Tandsæther
Constitutional chromosomal aberrations are rare in hematologic malignancies and their pathogenetic role is mostly poorly understood. We present a comprehensive molecular characterization of a novel constitutional chromosomal translocation found in two siblings - sisters - diagnosed with myelodysplastic syndrome (MDS).
-
Genomic Frequencies of Dynamic DNA Sequences and Mammalian Lifespan. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2024-4-27 Marianna Martella, Nadia Carlesso, Zoë A E Waller, Guido Marcucci, Flavia Pichiorri, Steven S Smith
Dynamic DNA sequences (i.e. sequences capable of forming hairpins, G-quadruplexes, i-motifs, and triple helices) can cause replication stress and associated mutations. One example of such a sequence occurs in the RACK7 gene in human DNA. Since this sequence forms i-motif structures at neutral pH that cause replication stress and result in spontaneous deletions in prostate cancer cells, our initial
-
Identification of a Gene Expression Signature to Predict the Risk of Early Recurrence and the Degree of Immune Cell Infiltration in Triple-negative Breast Cancer. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2024-4-27 Keiko Sato, Kentaro Miura, Shoma Tamori, Kazunori Akimoto
Patients with triple-negative breast cancer (TNBC) have a high rate of recurrence within 3 years of diagnosis and a high rate of death within 5 years compared to other subtypes. The number of clinical trials investigating various new agents and combination therapies has recently increased; however, current strategies benefit only a minority of patients. This study aimed to identify specific genes that
-
Fusion of Platelet Derived Growth Factor Receptor Alpha (PDGFRA) With Ubiquitin Specific Peptidase 8 (USP8) in a Calcified Chondroid Mesenchymal Neoplasm Harboring t(4;15)(q12;q21) as a Sole Aberration. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2024-4-27 Ioannis Panagopoulos, Kristin Andersen, Ludmila Gorunova, Ingvild Lobmaier
The term "calcified chondroid mesenchymal neoplasm" was introduced in 2021 to describe a group of tumors characterized by various morphological features, including the formation of cartilage or chondroid matrix. These tumors frequently carry chimeric genes where the 5'-end partner gene is fibronectin 1 and the 3'-end partner gene codes for receptor tyrosine kinase. Our study explores fusion of the
-
Genetic Analyses of Primary Liver Cancer Cell Lines: Correspondence With Morphological Features of Original Tumors. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2024-4-27 Jun Akiba, Sachiko Ogasawara, Hirohisa Yano
Advancements in genetic analysis technologies have led to establishment of molecular classifications systems for primary liver cancers. The correlation between pathological morphology and genetic mutations in hepatocellular carcinoma (HCC) is becoming increasingly evident. To construct appropriate experimental models, it is crucial to select cell lines based on their morphology and genetic mutations
-
Deregulated circRNAs in Epithelial Ovarian Cancer With Activity in Preclinical In Vivo Models: Identification of Targets and New Modalities for Therapeutic Intervention. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2024-04-26 Ulrich H Weidle, Fabian Birzele
Epithelial ovarian cancer (EOC) is associated with a dismal prognosis due to development of resistance to chemotherapy and metastasis in the peritoneal cavity and distant organs. In order to identify new targets and treatment modalities we searched the literature for up- and and down-regulated circRNAs with efficacy in preclinical EOC-related in vivo systems. Our search yielded circRNAs falling into
-
The Important Role of GPX1 and NF-κB Signaling Pathway in Human Gastric Cancer: Implications for Cell Proliferation and Invasion. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2024-04-26 Byeong Il Jang, Ji Yoon Jung, Sung Ae Koh, Kyung Hee Lee
Glutathione peroxidases (GPXs) are crucial antioxidant enzymes, counteracting reactive oxygen species (ROS). GPX overexpression promotes proliferation and invasion in cancer cells. Glutathione peroxidase-1 (GPX1), the most abundant isoform, contributes to invasion, migration, cisplatin resistance, and proliferation in various cancers. Nuclear factor-kappa B (NF-[Formula: see text]B) participates in
-
CUL4A Ubiquitin Ligase Is an Independent Predictor of Overall Survival in Pancreatic Adenocarcinoma. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2024-3-1 Panagiotis Tavlas, Sofia Nikou, Christina Geramoutsou, Pinelopi Bosgana, Spyridon Champeris Tsaniras, Maria Melachrinou, Ioannis Maroulis, Vasiliki Bravou
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with dismal prognosis. Genomic instability due to defects in cell-cycle regulation/mitosis or deficient DNA-damage repair is a major driver of PDAC progression with clinical relevance. Deregulation of licensing of DNA replication leads to DNA damage and genomic instability, predisposing cells to malignant transformation. While overexpression
-
Impact of Tumor Grade Distribution on Genetic Alterations in Clear Cell Renal Cell Carcinoma and Prostate Cancer. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2024-3-1 Kosuke Mizutani, Seiji Sugiyama, Koji Kameyama, Shingo Kamei, Shigeaki Yokoi, Akemi Morikawa, Makoto Takeuchi, Kensaku Seike, Toru Yamada, Hidetoshi Ehara, Seiya Sawada, Kouseki Hirade, Hirohito Furuta, Kengo Matsunaga, Tetsuya Yamada, Ippei Sakamoto, Yasutaka Kato, Hiroshi Nishihara, Satoshi Ishihara, Takashi Deguchi
A genomic analysis based on next-generation sequencing is important for deciding cancer treatment strategies. Cancer tissue sometimes displays intratumor heterogeneity and a pathologic specimen may contain more than two tumor grades. Although tumor grades are very important for the cancer prognosis, the impact of higher tumor grade distribution in a specimen used for a genomic analysis is unknown.
-
PRIM2: A Marker of MYC-driven Hyper-proliferation, Disease Progression, Tumor Aggressiveness and Poor Survival in Glioma Patients. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2024-3-1 Ronghui Sun, Xiaodong Shao, Farhana Akter, Kashif Rafiq Zahid, Shun Yao, Lianting Ma, Guozheng Xu
Gliomas are the most prevalent brain tumors with metabolic alterations playing a pivotal role in disease progression. However, the precise coordination of metabolic alterations with tumor-promoting cellular mechanisms, leading to tumor initiation, progression, and aggressiveness, resulting in poor outcomes, remains poorly understood in gliomas.
-
Association of Androgen Receptor and PD-L1 Expression in Upper Urinary Tract Urothelial Carcinoma. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2024-3-1 Yohei Okuda, Taigo Kato, Kazutoshi Fujita, Hiroaki Fushimi, Hiroshi Miyamoto, George J Netto, Norio Nonomura
The response to immune checkpoint inhibitors (ICIs) or enfortumab vedotin is limited in patients with upper urinary tract urothelial carcinoma (UTUC), and the development of new targeted therapy for UTUC is eagerly needed. Several biomarkers, including programmed cell death-ligand 1 (PD-L1), have already been reported as predictors of response to ICIs therapy for UTUC. Recently, several studies have
-
Thioredoxin Reductase Inhibitor Suppresses the Local Progression of Rhabdomyosarcoma With PDX Models. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2024-3-1 Hideyuki Kinoshita, Seiko Kinoshita, Hiroto Kamoda, Yoko Hagiwara, Seiji Ohtori, Tsukasa Yonemoto
Chemoresistance in rhabdomyosarcoma (RMS) is associated with poor survival, necessitating the development of novel anticancer drugs. Auranofin (AUR), an anti-rheumatic drug, is a thioredoxin reductase (TXNRD) inhibitor with anticancer properties. Although patient-derived xenograft (PDX) models are essential for studying cancer biology, reports on sarcomas using the PDX model are scarce because of their
-
CircRNAs as New Therapeutic Entities and Tools for Target Identification in Acute Myeloid Leukemia. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2024-3-1 Adam Nopora, Ulrich H Weidle
Acute myeloid leukemia (AML) is a genetically extremely heterogeneous disease. Drug resistance after induction therapy is a very frequent event resulting in poor medium survival times. Therefore, the identification of new targets and treatment modalities is a medical high priority issue. We addressed our attention to circular RNAs (circRNAs), which can act as oncogenes or tumor suppressors in AML.
-
Non-homologous End-joining Genotype, mRNA Expression, and DNA Repair Capacity in Childhood Acute Lymphocytic Leukemia. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2024-3-1 Chao-Chun Chen, Wen-Shin Chang, Jen-Sheng Pei, Chien-Chung Kuo, Chung-Hsing Wang, Yun-Chi Wang, Pei-Chen Hsu, Jie-Long He, Jian Gu, DA-Tian Bau, Chia-Wen Tsai
The capacity for non-homologous end-joining (NHEJ) repair plays a pivotal role in maintaining genome stability and in carcinogenesis. However, there is little literature on the involvement of NHEJ-related genes in childhood acute lymphocytic leukemia (ALL). Our study aimed to elucidate the impact of polymorphisms of X-ray repair cross-complementing group 4 (XRCC4) (rs6869366, rs2075685, rs2075686,
-
POLD1 Is Required for Cell Cycle Progression by Overcoming DNA Damage in Malignant Pleural Mesothelioma. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2024-3-1 Daiki Shimizu, Miku Ishibashi, Tadaaki Yamada, Yuki Toda, Shigekuni Hosogi, Eishi Ashihara
The prognosis of patients with malignant pleural mesothelioma (MPM) remains poor due to lack of effective therapeutic targets. DNA damage caused by long-time exposure to asbestos fibers has been associated with the development of MPM, with mutations at genes encoding DNA damage repair (DDR)-related molecules frequently expressed in patients with MPM. The present study was designed to identify novel
-
CXCL10 Expression in Human Colorectal Cancer Tissue and its Correlation With Serum Levels of CXCL10. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-12-28 Lianbo Li, Kosuke Kanemitsu, Koji Ohnishi, Rin Yamada, Hiromu Yano, Yukio Fujiwara, Yuji Miyamoto, Yoshiki Mikami, Taizo Hibi, Hideo Baba, Yoshihiro Komohara
CXCL10, a member of the CXC chemokine family, plays a crucial role in immune response by facilitating the chemotaxis of CXCR3-positive immune cells. We examined the expression of CXCL10 to unravel its functional significance in colorectal cancer.
-
Single-cell Transcriptomic Analysis Reveals an Immunosuppressive Network Between POSTN CAFs and ACKR1 ECs in TKI-resistant Lung Cancer. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-12-28 Zhiyi Wang, Ning Yan, Hailong Sheng, Yazhi Xiao, Jingyuan Sun, Chuanhui Cao
Tyrosine kinase inhibitor (TKI) therapy, a principal treatment for advanced non-small cell lung cancer (NSCLC), frequently encounters the development of drug resistance. The tumor microenvironment (TME) plays a critical role in the progression of NSCLC, yet the relationship between endothelial cells (ECs) and cancer-associated fibroblasts (CAFs) subpopulations in TKI treatment resistance remains largely
-
Genetic Characterization of Pediatric Mixed Phenotype Acute Leukemia (MPAL). Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-12-28 Ioannis Panagopoulos, Kristin Andersen, Inga Maria Rinvoll Johannsdottir, Maren Randi Tandsæther, Francesca Micci, Sverre Heim
Mixed phenotype acute leukemia (MPAL) is a rare hematologic malignancy in which the leukemic cells cannot be assigned to any specific lineage. The lack of well-defined, pathogenetically relevant diagnostic criteria makes the clinical handling of MPAL patients challenging. We herein report the genetic findings in bone marrow cells from two pediatric MPAL patients.
-
Metastatic Lymph Node 64 (MLN64) Expression in Gastric Cancer: The Clinical and Molecular Implications in Drug Resistance. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-12-28 Amber Xinyu Li, Jimmy Jianyuan Zeng, Elyas Khan, Q Ping Dou, Xinguo Zhuang, Edison Ke Ji, Fiona Ruge, Tracey A Martin, Shuqin Jia, Wen G Jiang
Metastatic lymph node 64 (MLN64) is often co-amplified with ERBB2 (HER2) and plays a role in the progression of breast and prostate cancer. The present study explored the expression of MLN64 in clinical gastric cancer in association with the ERBB family and its impact on drug resistance in patients.
-
Irradiated Cell-derived Exosomes Enhance Cell Proliferation and Radioresistance via the MAPK/Erk Pathway. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-12-28 Yue Dong, Keisuke Tamari, Maiko Kishigami, Shohei Katsuki, Kazumasa Minami, Shotaro Tatekawa, Shinichi Shimizu, Masahiko Koizumi, Kazuhiko Ogawa
Radiation therapy is pivotal in cancer treatment; however, its efficacy is limited by challenges such as tumor recurrence. This study delves into the role of exosomes, which are molecular cargo-bearing vesicles, in influencing cell proliferation, radioresistance, and consequent post-irradiation tumor recurrence. Given the significance of exosomes from irradiated malignancies in diagnostics and therapy
-
Development and Validation of Potential Molecular Subtypes and Signatures of Thyroid Carcinoma Based on Aging-related Gene Analysis. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-12-28 Zhi Li, L I Jia, Huang-Ren Zhou, L U Zhang, Meng Zhang, Juan Lv, Zhi-Yong Deng, Chao Liu
Thyroid carcinoma (THCA) is a cancer of the endocrine system that most commonly affects women. Aging-associated genes play a critical role in various cancers. Therefore, we aimed to gain insight into the molecular subtypes of thyroid cancer and whether senescence-related genes can predict the overall prognosis of THCA patients.
-
Depletion of DNTTIP2 Induces Cell Cycle Arrest in Pancreatic Cancer Cells. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-12-28 Masato Yoshizawa, Atsushi Shiozaki, Eishi Ashihara
Pancreatic cancer is one of the most lethal malignant cancers worldwide and the seventh most common cause of cancer-related death in both sexes. Herein, we analyzed open access data and discovered that expression of a gene called deoxynucleotidyltransferase terminal-interacting protein 2 (DNTTIP2) is linked to prognosis of pancreatic ductal adenocarcinoma (PDAC). We then elucidated the role of DNTTIP2
-
Identification of TTC21A as a Potential Prognostic Marker in Head and Neck Squamous Cell Carcinoma: In Silico Analysis. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-12-28 Lili Wang, Yanping Yin, Peng Liu, Hanxiang Chen, Miao Xu
Tetratricopeptide repeat domain 21A (TTC21A) plays a crucial role in ciliary function and has been associated with various pathogenic processes, including carcinogenesis. However, its role in head and neck squamous cell carcinoma (HNSCC) has not been elucidated.
-
Impact of Mutations in Subunit Genes of the Mammalian SWI/SNF Complex on Immunological Tumor Microenvironment. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-12-28 Chikako Hozumi, Akira Iizuka, Tomoatsu Ikeya, Haruo Miyata, Chie Maeda, Tadashi Ashizawa, Takeshi Nagashima, Kenichi Urakami, Yuji Shimoda, Keiichi Ohshima, Koji Muramatsu, Takashi Sugino, Akio Shiomi, Yasuhisa Ohde, Etsuro Bando, Kenichiro Furukawa, Teiichi Sugiura, Takashi Mukaigawa, Seiichiro Nishimura, Yasuyuki Hirashima, Koichi Mitsuya, Shusuke Yoshikawa, Yasuhiro Tsubosa, Hirohisa Katagiri, Masashi
Recently, inactivating somatic mutations of SWI/SNF chromatin-remodeling genes in cancers have been reported. However, few studies have been performed regarding the immunological analysis of the tumor microenvironment (TME) in chromatin remodeling complex gene-mutated tumors. In the present study, we identified cancer patients harboring various mammalian SWI/SNF complex mutations and investigated the
-
Clinical Significance of Multi-Cancer Genome Profiling: Data from a Single Hospital in Japan. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-12-28 Rika Aoyama, Hinano Nishikubo, Kyoka Kawabata, Saki Kanei, Yurie Yamamoto, Sadaaki Nishimura, Masakazu Yashiro
Multi-cancer genome profiling (multi-CGP) testing intends to predict the therapeutic efficacy of anticancer medication treatments for eligible patients as part of "precision cancer care." The number of cases in which a new treatment was applied based on multi-CGP testing has been reported to be between 10% and 20% for all patients in Japan. This study aimed to determine the significance of multi-CGP
-
Network and Computational Drug Repurposing Analysis for c-Myc Inhibition in Burkitt Lymphoma. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-12-1 Yongmin Lee, Seungyoon Nam
The treatment rate of Burkitt lymphoma (BL) is still low in low-income countries and among elderly patients. The c-Myc dysregulation induced by mutations is one of the characteristics of BL. However, studies on the downstream signaling pathways of c-Myc are still lacking. This study aimed to identify the signaling pathways regulated by c-Myc.
-
Bayesian Approaches in Exploring Gene-environment and Gene-gene Interactions: A Comprehensive Review. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-12-1 N A Sun, Y U Wang, Jiadong Chu, Qiang Han, Yueping Shen
Rapid advancements in high-throughput biological techniques have facilitated the generation of high-dimensional omics datasets, which have provided a solid foundation for precision medicine and prognosis prediction. Nonetheless, the problem of missing heritability persists. To solve this problem, it is essential to explain the genetic structure of disease incidence risk and prognosis by incorporating
-
Effect of NFATc2- and Sp1-mediated TNFalpha Regulation on the Proliferation and Migration Behavior of Pancreatic Cancer Cells. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-12-1 Manuela Malsy, Bernhard Graf, Elisabeth Bruendl, Constantin Maier-Stocker, Anika Bundscherer
One in two people will develop a tumor during their lifetime. Adenocarcinoma of the pancreas is one of the most aggressive types of cancer in humans with very poor long-term survival. A central role in the carcinogenesis of pancreatic cancer has been attributed to NFAT transcription factors. Previous studies have identified the transcription factor Sp1 as a binding partner of NFATc2 in pancreatic cancer
-
Orexins and Prostate Cancer: State of the Art and Potential Experimental and Therapeutic Perspectives. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-12-1 Anna Costagliola, Renato Lombardi, Giovanna Liguori, Andrea Morrione, Antonio Giordano
Prostate cancer (PCa) is the second most common cancer in humans. Peptides have recently been used as targeted therapeutics in cancers, due to their extensive multi-functional applications. Two hypothalamic peptides, orexins A (OXA) and B (OXB) and their specific receptors, orexin receptor 1 (OX1R) and 2 (OX2R), orchestrate several biological processes in the central nervous system and peripheral organs
-
Kinase D-interacting Substrate of 220 kDa Is Overexpressed in Gastric Cancer and Associated With Local Invasion. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-12-1 Shuo Cai, Zhiwei Sun, Xiangyu Gao, K E Ji, Fiona Ruge, Deepa Shankla, Xiangyi Liu, Wen G Jiang, Lin Ye
Kinase D-interacting substrate of 220 kDa (Kidins220), also known as ankyrin repeat-rich membrane spanning protein (ARMS), is a transmembrane scaffold protein. Deregulated Kidins220 has been observed in various malignancies including melanoma, glioma, neuroblastoma, prostate cancer, pancreatic cancer, and ovarian cancer.
-
Circular RNA in Non-small Cell Lung Carcinoma: Identification of Targets and New Treatment Modalities. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-12-1 Ulrich H Weidle, Fabian Birzele
Despite availability of several treatment options for non-small cell lung cancer (NSCLC), such as surgery, chemotherapy, radiation, targeted therapy and immunotherapy, the survival rate of patients for five years is in the range of 22%. Therefore, identification of new targets and treatment modalities for this disease is an important issue. In this context, we screened the PubMed database for up-regulated
-
Fucoxanthin Inhibits Development of Sigmoid Colorectal Cancer in a PDX Model With Alterations of Growth, Adhesion, and Cell Cycle Signals. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-12-1 Masaru Terasaki, Kirara Tsuruoka, Takuji Tanaka, Hayato Maeda, Masaki Shibata, Kazuo Miyashita, Yukihide Kanemitsu, Shigeki Sekine, Mami Takahashi, Shigehiro Yagishita, Akinobu Hamada
Fucoxanthin (Fx), a dietary marine xanthophyll, exerts potent anticancer effects in various colorectal cancer (CRC) animal models. However, therapeutic effects of Fx in human cancer tissues remain unclear. A patient-derived xenograft (PDX) mouse model transplanted with cancer tissues from patients is widely accepted as the best preclinical model for evaluating the anticancer potential of drug candidates
-
SNHG3/WISP2 Axis Promotes Hela Cell Migration and Invasion via Activating Wnt/β-Catenin Signaling. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-12-1 Dengfei Xu, Hao Feng, Zirui Ren, Xiang Li, Chenyang Jiang, Yuming Chen, Lina Liu, Wenchao Chen, Zhilei Cui, Shundong Cang
Cervical cancer (CC) poses a significant threat to women's health and has a relatively poor prognosis due to local invasion and metastasis. It is, therefore, crucial to elucidate the molecular mechanisms of CC metastasis. SNHG3 has been implicated in various tumor metastasis processes, but its involvement in CC has not been thoroughly studied. Our study aimed to investigate the role of SNHG3 in metastasis
-
The Combination of Methioninase and Ethionine Exploits Methionine Addiction to Selectively Eradicate Osteosarcoma Cells and Not Normal Cells and Synergistically Down-regulates the Expression of C-MYC. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-12-1 Yusuke Aoki, Yutaro Kubota, Qinghong Han, Noriyuki Masaki, Koya Obara, Michael Bouvet, Sant P Chawla, Yasunori Tome, Kotaro Nishida, Robert M Hoffman
The fundamental and general hallmark of cancer cells, methionine addiction, termed the Hoffman effect, is due to overuse of methionine for highly-increased transmethylation reactions. In the present study, we tested if the combination efficacy of recombinant methioninase (rMETase) and a methionine analogue, ethionine, could eradicate osteosarcoma cells and down-regulate the expression of c-MYC.
-
Preoperative ctDNA Levels Are Associated With Poor Overall Survival in Patients With Ovarian Cancer. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-12-1 Arturas Dobilas, Yilun Chen, Christian Brueffer, Pia Leandersson, Lao H Saal, Christer Borgfeldt
Circulating tumor DNA (ctDNA), which is shed from cancer cells into the bloodstream, offers a potential minimally invasive approach for cancer diagnosis and monitoring. This research aimed to assess the preoperative ctDNA levels in ovarian tumors patients' plasma and establish correlations with clinicopathological parameters and patient prognosis.
-
Phosphoglycerate-kinase-1 Is a Potential Prognostic Biomarker in HNSCC and Correlates With Immune Cell Infiltration. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-12-1 Ping Wang, Yue-Yue Wang, Yang-Long Xu, Chun-Yu Zhang, Kun Wang, Qian Wang
Head and neck squamous cell carcinoma (HNSCC) is the sixth leading cancer worldwide, with a high recurrence rate and a low cure rate. Phosphoglycerate kinase 1 (PGK1), an essential enzyme in the aerobic glycolysis pathway, is a prognostic marker for a variety of cancers. However, it remains unclear whether a PGK1-based immune signature can be used as a prognostic biomarker in HNSCC patients.
-
(S)-3-(3-Fluoro-4-Methoxybenzyl)-5,6,7-Trimethoxychroman-4-One Suppresses the Proliferation of Huh7 Cells by Up-regulating P21 and Inducing G2/M Phase Arrest. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-12-1 Haelim Yoon, Junho Lee, Sangil Kwon, Seung-Yong Seo, Sayeon Cho
Hepatocellular carcinoma (HCC) is a prevalent type of cancer worldwide. Although sorafenib is the only chemotherapy agent used for HCC, there is a need to discover a more potent anticancer agent with reduced side-effects. The compound, (S)-3-(3-fluoro-4-methoxybenzyl)-5,6,7-trimethoxychroman-4-one (FMTC), was designed to inhibit tubulin assembly but its specific mechanisms of action have not been previously
-
SUV39H1 Expression as a Guideline for Omitting Radiotherapy in Lymph Node-positive Triple-negative Breast Cancer Patients. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-10-27 Wei-Lun Huang, Chi-Wen Luo, Huei-Shan Lin, Chao-Ming Hung, Fang-Ming Chen, Sin-Hua Moi, Mei-Ren Pan
The role of postoperative radiotherapy (RT) combined with chemotherapy (CT) for lymph node-positive (LN+) triple-negative breast cancer (TNBC) remains controversial. SUV39H1-mediated epigenetic regulation is associated with cancer cell migration, invasion, metastasis, and treatment resistance. This study aims to identify the role of SUV39H1 in TNBCs.
-
Inhibition of Increased Invasiveness of Breast Cancer Cells With Acquired Tamoxifen Resistance by Suppression of CYR61. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-10-27 Gerd Bauerschmitz, Silke Hüchel, Julia Gallwas, Carsten Gründker
Hormone sensitivity-targeted therapy with selective estrogen receptor modulators (SERMs), such as 4-hydroxytamoxifen (4-OHT), is the mainstay of treatment for breast cancers (BCs) that express estrogen receptor α (ERα). However, development of resistance limits this therapy approach. The question arises whether changes associated with 4-OHT resistance could be exploited therapeutically.
-
Hsa_circ_0079557 Promotes the Proliferation of Colorectal Cancer Cells Through the hsa_circ_0079557/miR-502-5p/CCND1 Axis. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-10-27 Chao Yu, Xue Huang, Renli Huang, Peiqi Wang, Zongda Cai, Zeyi Guo, Qingnan Lan, Haodi Cao, Jinlong Yu
Recent studies have demonstrated the crucial regulatory roles of circular RNAs (circRNAs) in cancer initiation and progression. The sponge mechanism of circRNAs has been shown to be widely active in various types of tumors. However, many circRNAs still have not been verified to function through this mechanism. This study aimed to investigate the regulatory mechanism of hsa_circ_0079557 in colorectal
-
Clinicopathological and Prognostic Values of Telomerase Reverse Transcriptase (TERT) Promoter Mutations in Ovarian Clear Cell Carcinoma for Predicting Tumor Recurrence, Platinum Resistance and Survival. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-10-27 Hyunwoo Yoo, Hyun-Soo Kim
A small subset of patients with ovarian clear cell carcinoma (OCCC) harbors telomerase reverse transcriptase promoter (TERTp) mutations. We aimed to analyze the clinicopathological and molecular characteristics of TERTp-mutant OCCC and investigate whether TERTp mutations are associated with the clinicopathological characteristics and outcomes of patients with OCCC.
-
Potential Common Molecular Mechanisms Between Periodontitis and Hepatocellular Carcinoma: A Bioinformatic Analysis and Validation. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-10-27 Xiaomiao Fan, Zimin Song, Wenguang Qin, Ting Yu, Baogang Peng, Yuqin Shen
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and has a poor prognosis. Periodontitis, or tooth loss, is considered to be related to hepatocarcinogenesis and its poor prognosis. This study aimed to explore potential associations and cross-talk mechanisms between periodontitis and HCC.
-
p21 Protein Outperforms Clinico-pathological Criteria in Predicting Liver Metastases in Pancreatic Endocrine Tumors. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-10-27 Aejaz Nasir, Malik K Ahmed, James J Saller, Evita B Henderson-Jackson, Mokenge P Malafa, Timothy J Yeatman, Domenico Coppola
P21 is a cyclin-dependent kinase inhibitor regulating the cell cycle as a tumor suppressor. Using a p21 immunohistochemistry (IHC) assay, we compared tumor p21 levels with conventional clinico-pathological criteria in primary pancreatic endocrine tumor subsets with and without liver metastases.
-
Hepatocellular Carcinoma: Up-regulated Circular RNAs Which Mediate Efficacy in Preclinical In Vivo Models. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-10-27 Ulrich H Weidle, Adam Nopora
Hepatocellular carcinoma (HCC) ranges as number two with respect to the incidence of tumors and is associated with a dismal prognosis. The therapeutic efficacy of approved multi-tyrosine kinase inhibitors and checkpoint inhibitors is modest. Therefore, the identification of new therapeutic targets and entities is of paramount importance. We searched the literature for up-regulated circular RNAs (circRNAs)
-
Risk Stratification by Tissue GAD1 Expression Level in Curatively Resected Esophageal Squamous Cell Carcinoma. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-10-27 Takayoshi Kishida, Mitsuro Kanda, Yusuke Sato, Dai Shimizu, Yoshikuni Inokawa, Norifumi Hattori, Masamichi Hayashi, Chie Tanaka, Goro Nakayama, Yasuhiro Kodera
To improve patient management, new biomarkers are required that stratify prognosis. Here we focused on glutamic acid decarboxylase 1 (GAD1), which is associated with proliferation of lung cancer cells, and investigated its expression and function in esophageal squamous cell carcinoma (ESCC).
-
Pathogenetic Dichotomy in Angioleiomyoma. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-10-27 Ioannis Panagopoulos, Kristin Andersen, Marta Brunetti, Ludmila Gorunova, Ilyá Kostolomov, Wanja Kildal, Hanne Regine Hognestad, Ingvild Lobmaier, Francesca Micci, Sverre Heim
Angioleiomyoma is a benign tumor, occurs at any age, and arises most frequently in the lower extremities. Genetic information on angioleiomyomas is restricted to six reported abnormal karyotypes, losses in chromosome 22 and gains in Xq found by comparative genomic hybridization, and mutation analysis of notch receptor 2 (NOTCH2), NOTCH3, platelet-derived growth factor receptor beta (PDGFRB), and mediator
-
Using Comparative Proteomics to Identify Protein Signatures in Clear Cell Renal Cell Carcinoma. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-10-27 Juhee Park, Eun Hye Lee, Hyunchae Sim, Ann-Yae Na, So Young Choi, Jae-Wook Chung, Yun-Sok Ha, Tae Gyun Kwon, Sangkyu Lee, Jun Nyung Lee
Renal cell carcinoma (RCC) is one of the most commonly diagnosed cancers in the world. Approximately 25-30% of patients identified with initial kidney cancer will have metastasized tumors, thus 5-year survival rates for these patients are poor. Therefore, biomarker research is required to identify and predict molecular signatures in RCC.
-
Molecular Characteristics and Therapeutic Vulnerabilities of Claudin-low Breast Cancers Derived from Cell Line Models. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-10-27 Ioannis A Voutsadakis
Breast cancers constitute heterogeneous tumor groups and their categorization in subtypes based on the expression of the estrogen (ER), progesterone (PR) and HER2 receptors has advanced therapeutics. Claudin-low breast cancer has been proposed as an additional subtype which is mostly ER, PR and HER2 negative, but its identification has not led to corresponding specific treatments yet.
-
Genetic Pathways in Peritoneal Mesothelioma Tumorigenesis. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-7-4 Ioannis Panagopoulos, Kristin Andersen, Marta Brunetti, Ludmila Gorunova, Ben Davidson, Marius Lund-Iversen, Francesca Micci, Sverre Heim
Mesotheliomas are tumors similar to, and probably derived from, mesothelial cells. They carry acquired chromosomal rearrangements, deletions affecting CDKN2A, pathogenetic polymorphisms in NF2, and fusion genes which often contain the promiscuous EWSR1, FUS, and ALK as partner genes. Here, we report the cytogenomic results on two peritoneal mesotheliomas.
-
Next Generation Sequencing Analysis and its Benefit for Targeted Therapy of Lung Adenocarcinoma. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-7-4 Vlastimil Kulda, Jiri Polivka, Martin Svaton, Tomas Vanecek, Marcela Buresova, Katerina Houfkova, Mahyar Sharif Bagheri, Tereza Knizkova, Bohuslava Vankova, Jindra Windrichova, Petr Macan, Vaclav Babuska, Martin Pesta
Targeted therapy has become increasingly important in treating lung adenocarcinoma, the most common subtype of lung cancer. Next-generation sequencing (NGS) enables precise identification of specific genetic alterations in individual tumor tissues, thereby guiding targeted therapy selection. This study aimed to analyze mutations present in adenocarcinoma tissues using NGS, assess the benefit of targeted
-
Bioinformatics Analysis of Novel Targets for Treating Cervical Cancer by Immunotherapy Based on Immune Escape. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-7-4 Ying-Hao Han, DA-Yu Ma, Seung-Jae Lee, Ying-Ying Mao, Shuai-Yang Sun, Mei-Hua Jin, Hu-Nan Sun, Taeho Kwon
Cervical cancer (CC) is a high-risk disease in women, and advanced CC can be difficult to treat even with surgery, radiotherapy, and chemotherapy. Hence, developing more effective treatment methods is imperative. Cancer cells undergo a renewal process to escape immune surveillance and then attack the immune system. However, the underlying mechanisms remain unclear. Currently, only one immunotherapy
-
Involvement of AKT/PI3K Pathway in Sanguinarine's Induced Apoptosis and Cell Cycle Arrest in Triple-negative Breast Cancer Cells. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-7-4 Samia S Messeha, Sophie Noel, Najla O Zarmouh, Tracy Womble, Lekan M Latinwo, Karam F A Soliman
Chemotherapy resistance in triple-negative breast cancer (TNBC) cells is well documented. Therefore, it is necessary to develop safer and more effective therapeutic agents to enhance the outcomes of chemotherapeutic agents. The natural alkaloid sanguinarine (SANG) has demonstrated therapeutic synergy when coupled with chemotherapeutic agents. SANG can also induce cell cycle arrest and trigger apoptosis
-
Localization of EGFR Mutations in Non-small-cell Lung Cancer Tissues Using Mutation-specific PNA-DNA Probes. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-7-4 Hajime Shigeto, Haruo Miyata, Tadashi Ashizawa, Akira Iizuka, Yasufumi Kikuchi, Chikako Hozumi, Chie Maeda, Ken Yamaguchi, Shohei Yamamura, Yasuto Akiyama
Epidermal growth factor receptor (EGFR) signaling inhibitors are potent therapeutic agents for EGFR-mutant non-small-cell lung cancer, but the effects of such inhibitors on the localization of EGFR mutations in tumor tissues remain to be elucidated. Thus, a simple and efficient technology for the detection of mutations in tumor tissue specimens needs to be developed.
-
Acute Undifferentiated Leukemia With a Balanced t(5;10)(q35;p12) Resulting in Fusion of HNRNPH1 With MLLT10. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-7-4 Ioannis Panagopoulos, Kristin Andersen, Hilde Skuterud Wik, Maren Randi Tandsæther, Francesca Micci, Sverre Heim
Acute undifferentiated leukemia (AUL) is leukemia which does not express lineage-specific antigens. Such cases are rare, accounting for 2.7% of all acute leukemia. The reported genetic information of AULs is limited to less than 100 cases with abnormal karyotypes and a few cases carrying chimeric genes or point mutation of a gene. We herein present the genetic findings and clinical features of a case
-
Targeted Therapy for BRAF V600E Positive Pancreatic Adenocarcinoma: Two Case Reports. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-7-4 Shivani Shah, Tabeer Rana, Pragnan Kancharla, Dulabh Monga
Pancreatic ductal adenocarcinoma (PDAC) is a malignancy that typically portends a poor prognosis, with a median overall survival ranging from eight to twelve months in patients with metastatic disease. Novel modalities of therapy, primarily targeted therapy, are now considered for patients with targetable mutations, such as BRAF mutations based on next generation sequencing. BRAF mutations specifically
-
Targeting Autophagy With the Synergistic Combination of Chloroquine and Rapamycin as a Novel Effective Treatment for Well-differentiated Liposarcoma. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-7-4 Noriyuki Masaki, Yusuke Aoki, Koya Obara, Yutaro Kubota, Michael Bouvet, Jun Miyazaki, Robert M Hoffman
Liposarcoma is a type of soft-tissue sarcoma arising from fat tissue. It is relatively common among soft-tissue sarcomas. Chloroquine (CQ), an antimalarial drug, can inhibit autophagy and induce apoptosis in cancer cells. Rapamycin (RAPA) is an inhibitor of mTOR. The combination of RAPA and CQ is a strong inhibitor of autophagy. Previously, we showed that the combination of RAPA and CQ was effective
-
OPLAH Protein Expression Stratifies the Prognosis of Patients With Squamous Cell Carcinoma of the Esophagus. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-7-4 Dai Shimizu, Mitsuro Kanda, Takayoshi Kishida, Shunsuke Nakamura, Masahiro Sasahara, Sei Ueda, Yusuke Sato, Yoshikuni Inokawa, Norifumi Hattori, Masamichi Hayashi, Chie Tanaka, Satoru Motoyama, Yasuhiro Kodera
Squamous cell carcinoma is one of the major subtypes of esophageal carcinoma, and the 5-year overall survival rate of esophageal squamous cell carcinoma patients who underwent curative treatment remains below 40%. We aimed to detect and validate the prognosticators of esophageal squamous cell carcinoma in patients who underwent radical esophagectomy.
-
Combination of Urinary MiR-501 and MiR-335 With Current Clinical Diagnostic Parameters as Potential Predictive Factors of Prostate Biopsy Outcome. Cancer Genom. Proteom. (IF 2.5) Pub Date : 2023-4-24 Jaroslav Juracek, Marie Madrzyk, Karolina Trachtova, Michaela Ruckova, Julia Bohosova, Dominik A Barth, Martin Pichler, Michal Stanik, Ondrej Slaby
The detection of prostate cancer (PCa) is currently based on prostate-specific antigen (PSA) quantification as an initial screening followed by ultrasound-guided transrectal biopsy. However, the high rate of false-negative biopsies often leads to inappropriate treatment. Therefore, new molecular biomarkers, such as urine microRNAs (miRNAs), are a possible way to redefine PCa diagnostics.